Venlafaxine, paroxetine and milnacipran for major depressive disorder: A pragmatic 24-week study

Hui Yu Chuang, Yun Hsuan Chang, Ling Yi Cheng, Yu Shan Wang, Shiou Lan Chen, Shih Heng Chen, Chun Hsien Chu, I. Hui Lee, Po See Chen, Tzung Lieh Yeh, Yen Kuang Yang, Ru Band Lu

研究成果: Article

4 引文 斯高帕斯(Scopus)

摘要

Major depressive disorder (MDD), one of the most common psychiatric disorders in the world, is a serious, recurrent and chronic mental disorder, which is associated with significant psychosocial disability and economic burden. Until recently, short-term effectiveness of antidepressants has been measured in terms of patients’ response to the medications in significantly reduced depressive symptoms. Remission, a long-term elimination of symptoms and the restoration of normal functioning, has become the primary outcome of therapy. In the current study, the efficacy of three frequently prescribed antidepressants, venlafaxine (75-225 mg/day), paroxetine (20 mg/day) and milnacipran (100 mg/day), used in treating 249 MDD patients with Hamilton Rating Scale of Depression (HRSD17) scores higher than 16 was compared. Each patient was evaluated at week 0, 1, 2, 4, 8, 12, 16, 20 and 24 in a 24-week open-label study. Eighty-two patients took venlafaxine, 97 took paroxetine and 70 patients took milnacipran. No significant differences were found between the three groups in the response condition (HRSD17 scores decreased more than 50%) after 24 weeks of follow-up. For remission, the paroxetine was the least efficacious medication than either the milnacipran (HRSD17 ≤ 7) or the venlafaxine (HRSD17 ≤ 5) by the last observation carried forward (LOCF) analysis. Our results suggest that the absence of depressive symptoms alone may not be an indicator for MDD remission, but the duration of absent depressive symptoms may be a better indicator.

原文English
頁(從 - 到)265-270
頁數6
期刊Chinese Journal of Physiology
57
發行號5
DOIs
出版狀態Published - 2014 一月 1

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)

指紋 深入研究「Venlafaxine, paroxetine and milnacipran for major depressive disorder: A pragmatic 24-week study」主題。共同形成了獨特的指紋。

  • 引用此